TITLE

Evaluation of the Validity of Preemptive Therapy against Cytomegalovirus Disease Based on Antigenemia Assay with a Cutoff of 20 Positive Cells per Two Slides

AUTHOR(S)
Sakamoto, Kana; Nakasone, Hideki; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Kawamura, Koji; Ashizawa, Masahiro; Sato, Miki; Terasako-Saito, Kiriko; Machishima, Tomohito; Kimura, Shun-Ichi; Kikuchi, Misato; Kako, Shinichi; Kanda, Junya; Yamazaki, Rie; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu
PUB. DATE
September 2013
SOURCE
PLoS ONE;Sep2013, Vol. 8 Issue 9, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background:Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT). However, the appropriate threshold of antigenemia-positive cells for deciding when to start GCV remains unclear. Patients:This retrospective study included 80 recipients who received HCT from an alternative donor between 2007 and 2011. In 2009, we switched the threshold from 3 (3A group, n=24) to 20 (20A group, n=56) antigenemia-positive cells per two slides for preemptive therapy after HCT from an alternative donor. Results:Early CMV disease within 100 days after HCT was observed in one patient in the 20A group. Antiviral agents including GCV, val-GCV, and foscarnet were given in 17 (71%) and 36 (64%) patients in the 3A and 20A groups, respectively (p=0.23). In 13 (23%) patients in the 20A group, the initiation of preemptive therapy was avoided because of the change in the cutoff value for CMV antigenemia. However, the total dose of GCV was not different between the two groups. The use of steroid was significantly associated with CMV antigenemia of at least 20 positive cells among patients with low-level antigenemia at the first detection. Conclusion:The increased threshold up to 20 positive cells for starting preemptive therapy was not associated with a significant increase in CMV disease, but the total dose of GCV was not reduced and there was one early CMV disease in the 20A group. We should explore how to identify patients who are at high risk for increased antigenemia among patients with low-level antigenemia, but at least, preemptive therapy should not be withheld in patients who are already receiving systemic steroid.
ACCESSION #
90531246

 

Related Articles

  • Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Barkam, Corinna; Kamal, Haytham; Dammann, Elke; Diedrich, Helmut; Buchholz, Stefanie; Eder, Matthias; Krauter, Jürgen; Ganser, Arnold; Stadler, Michael // Bone Marrow Research;2012, p1 

    Valganciclovir (VGC), an oral prodrug of ganciclovir (GCV), has been shown to clear cytomegalovirus (CMV) viremia in preemptive treatment of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), apparently without significant toxicity. Since VGC obviates hospitalization,...

  • Development of Herpes Simplex Virus Stomatitis during Receipt of Cidofovir Therapy. Dvorak, Christopher C.; Cowan, Morton J.; Horn, Biljana; Weintrub, Peggy S. // Clinical Infectious Diseases;10/15/2009, Vol. 49 Issue 8, pe92 

    We report 3 children who, after undergoing hematopoietic stem cell transplant, developed herpes simplex virus (HSV) stomatitis while receiving weekly cidofovir as preemptive treatment for cytomegalovirus infection. All patients responded well to treatment with either acyclovir or ganciclovir....

  • Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. Erard, Veronique; Guthrie, Katherine A.; Sachiko Seo; Smith, Jeremy; MeeiLi Huang; Jason Chien; Flowers, Mary E. D.; Corey, Lawrence; Boeckh, Michael // Clinical Infectious Diseases;7/1/2015, Vol. 61 Issue 1, p31 

    Background. Despite major advances in the prevention of cytomegalovirus (CMV) disease, the treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge. Methods. We examined recipient, donor, transplant, viral, and treatment factors associated with...

  • Intrathecal Administration of High-Titer Cytomegalovirus Immunoglobulin for Cytomegalovirus Meningitis. Shin-ichiro Fujiwara; Kazuo Muroi; Raine Tatara; Ken Ohmine; Tomohiro Matsuyama; Masaki Mori; Tadashi Nagai; Keiya Ozawa // Case Reports in Hematology;2014, p1 

    Cytomegalovirus (CMV) central nervous system disease after hematopoietic stem cell transplantation (HSCT) is a rare but life-threatening complication. Here, we report a patient who developed CMV meningitis after HSCT and was treated with the combination therapy of intrathecal high-titer CMV...

  • Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Berger, M.; Biasin, E.; Saglio, F.; Fagioli, F. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS101 

    First-line treatment of GVHD is based on steroids and produces sustained responses in 50–80% of patients with acute GVHD (aGVHD) and 40–50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with...

  • Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bonnet, D; Bhatia, M; Wang, J C Y; Kapp, U; Dick, J E // Bone Marrow Transplantation;2/1/99, Vol. 23 Issue 3, p203 

    Little is known about the cell types or mechanisms that underlie the engraftment process. Here, we have examined parameters affecting the engraftment of purified human Lin-CD34+CD38- normal and AML cells transplanted at limiting doses into NOD/SCID recipients. Mice transplanted with 500 to 1000...

  • Foscarnet.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p19 

    An abstract of the article "UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease," by K. Gregg and colleagues is presented.

  • Ganciclovir.  // Reactions Weekly;Jun2015, Vol. 1554 Issue 1, p94 

    An abstract of the article "Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping," by E. Drouot is presented.

  • Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Moretti, S; Zikos, P; Van Lint, M T; Tedone, E; Occhini, D; Gualandi, F; Lamparelli, T; Mordini, N; Berisso, G; Bregante, S; Bruno, B; Bacigalupo, A // Bone Marrow Transplantation;7/15/98, Vol. 22 Issue 2, p175 

    This trial was designed to compare foscarnet with ganciclovir as pre-emptive therapy for CMV infection in patients undergoing allogeneic hemopoietic stem cell transplant (HSCT). Thirty-nine patients were randomized to receive foscarnet 90 mg/kg every 12 h (n = 20) or ganciclovir 5 mg/kg every 12...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics